Humasis Co

Humasis Co Altman Z-Score

The Altman Z-Score of Humasis Co (205470.KQ) as of Nov 10, 2026 is 1.52. In the previous year, Altman Z-Score was 1.17 — a change of 29.73% (higher).

Altman Z-Score

1.52

YoY

29.73%

Last updated:

Altman Z-Score of Humasis Co is 2025 1.52 . Altman Z-Score of Humasis Co was 2024 1.17 . It decreases by 29.73% higher compared to the previous year.

The Humasis Co Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
2.69 KRW
Jan 1, 2019
2.24 KRW
Jan 1, 2020
4.78 KRW
Jan 1, 2021
3.89 KRW
Jan 1, 2022
3.91 KRW
Jan 1, 2023
1.45 KRW
Jan 1, 2024
1.17 KRW
Jan 1, 2025
1.52 KRW
The Humasis Co Altman Z-Score history
YEARAltman Z-ScoreYoY
1.52+29.73%
1.17-19.19%
1.45-63.05%
3.91+0.62%
3.89-18.63%
4.78+113.04%
2.24-16.48%
2.69-32.73%
3.99-90.21%
40.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Altman Z-Score of Humasis Co is 1.52 in 2025.

On Eulerpool you can find the complete historical development of Altman Z-Score Humasis Co since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Humasis Co

All Key Metrics — Humasis Co